Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BGB-21447 + BGB-43395 + Fulvestrant |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BGB-21447 | BGB 21447|BGB21447 | BCL2 inhibitor 27 | Limited information is currently available on BGB-21447, a putative BCL2 inhibitor (Mar 2024). | |
BGB-43395 | BGB43395|BGB 43395 | CDK4 Inhibitor 17 | BGB-43395 selectively inhibits CDK4, potentially resulting in cell cycle arrest and decreased tumor cell proliferation (NCI Drug Dictionary). | |
Fulvestrant | Faslodex | ICI 182,780 | Hormone - Anti-estrogens 31 | Faslodex (fulvestrant) is a competitive inhibitor of estrogen that binds and deforms estrogen receptors, and causes inhibition of growth in cultured estrogen-sensitive breast cancer cells and is FDA approved for use in patients with hormone receptor-positive breast cancer (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06756932 | Phase I | BGB-21447 + BGB-43395 + Fulvestrant BGB-21447 + Fulvestrant | BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer | Recruiting | USA | AUS | 1 |